

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Ragosa Mark</u> (Last) (First) (Middle) C/O KINKSA PHARMACEUTICALS INT'L, PLC 105 PICCADILLY, SECOND FLOOR (Street) LONDON X0 W1J 7NJ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Kiniksa Pharmaceuticals International, plc</u> [<u>KNSA</u>]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>CHIEF FINANCIAL OFFICER</u>
	3. Date of Earliest Transaction (Month/Day/Year) 03/09/2026	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Class A Ordinary Share	03/09/2026		M ⁽¹⁾		2,036	A	\$22.89	14,122	D	
Class A Ordinary Share	03/09/2026		M ⁽¹⁾		10,513	A	\$17.76	24,635	D	
Class A Ordinary Share	03/09/2026		M ⁽¹⁾		13,813	A	\$18.06	38,448	D	
Class A Ordinary Share	03/09/2026		M ⁽¹⁾		10,360	A	\$26.74	48,808	D	
Class A Ordinary Share	03/09/2026		S ⁽¹⁾		17,981	D	\$45.58 ⁽²⁾	30,827	D	
Class A Ordinary Share	03/09/2026		S ⁽¹⁾		18,741	D	\$46.24 ⁽³⁾	12,086	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Share Option	\$22.89	03/09/2026		M ⁽¹⁾			2,036	(4)	03/15/2031	Class A Ordinary Share	2,036	\$0	0	D	
Share Option	\$17.76	03/09/2026		M ⁽¹⁾			10,513	(5)	08/31/2033	Class A Ordinary Share	10,513	\$0	18,396	D	
Share Option	\$18.06	03/09/2026		M ⁽¹⁾			13,813	(6)	03/31/2034	Class A Ordinary Share	13,813	\$0	19,337	D	
Share Option	\$26.74	03/09/2026		M ⁽¹⁾			10,360	(7)	08/31/2034	Class A Ordinary Share	10,360	\$0	22,790	D	

Explanation of Responses:

- This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$44.885 and \$45.88. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$45.89 and \$46.79. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- The option is fully vested and exercisable.
- The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
- The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.
- The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024.

/s/ Douglas Barry, Attorney-in- 03/11/2026

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.